 CAMBRIDGE, Mass., Feb. 17, 2021 GLOBE NEWSWIRE -- Codiak BioSciences, Inc. Nasdaq: CDAK Codiak, a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,162,500 shares of its common stock at a public offering price of 21.00 per share, which includes the exercise in full of the underwriters option to purchase 412,500 additional shares. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are anticipated to be approximately 66.4 million. The offering of the shares is expected to result in approximately 62.0 million in net proceeds to Codiak after deducting underwriting discounts and commissions and other estimated offering expenses payable by Codiak. 